首页 > 市场调查报告书 > 製药

循环系统

市场调查报告书

商品编码

1532509

心臟衰竭POC 和LOC 设备市场- 按测试类型（蛋白质体学、代谢组学、基因组学）、技术（微流体、基于阵列的系统）、最终用途（医院、专科诊所、辅助生活和家庭护理环境） - 全球预测（2024 年 -第2032章

Heart Failure POC and LOC Devices Market - By Test Type (Proteomic, Metabolomic, Genomic), Technology (Microfluidics, Array-based Systems), End-use (Hospitals, Specialty Clinics, Assisted Living & Homecare Settings) - Global Forecast (2024 - 2032)

出版日期: 2024年05月21日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在医疗基础设施改善的推动下，2024 年至 2032 年全球心臟衰竭 POC 和 LOC 设备市场复合年增长率将超过 16.4%。根据世界卫生组织的数据，2022 年全球医疗保健支出达到 8.3 兆美元，反映出对先进医疗技术的投资不断增长。

随着医疗保健系统的现代化，人们更加重视将先进的诊断技术融入日常实践中。这项发展提高了检测和管理心臟衰竭的可及性和效率。在已开发国家和新兴国家，对医疗保健设施的投资和技术的采用促进了心臟衰竭护理点 POC 和晶片实验室 LOC 设备的更广泛可用性，从而实现更快、更准确的诊断。这些进步满足了对创新诊断解决方案日益增长的需求，并改善了患者的治疗效果，有利于市场前景。

心臟衰竭 POC 和 LOC 设备产业根据技术、测试类型、最终用途和地区进行分类。

基于阵列的系统部分在预测期内将经历显着的复合年增长率，因为它们能够在单次测试中提供高通量分析。基于阵列的系统提供了一种多重方法，能够同时测量与心臟衰竭相关的多个生物标记。此功能提高了诊断准确性和效率，有助于更早检测和更有效地管理病情。随着医疗保健提供者寻求透过更详细和快速的诊断来优化患者的治疗结果，基于阵列的系统在用于心臟衰竭的 POC 和 LOC 设备中的采用预计会增加。

由于对个人化医疗的需求不断增长，到 2032 年，代谢组学检测领域将占据显着的市场份额。该测试提供了对代谢特征的详细了解，从而提高了心臟衰竭诊断和管理的准确性。随着医疗保健日益转向个人化方法，在护理点或透过晶片实验室技术进行快速、详细分析的能力支持更客製化的治疗计划。这种向精准医学的转变推动了对先进诊断设备的需求，这些设备可以快速提供全面的代谢资料，改善患者的治疗结果。

由于对创新医疗解决方案和高医疗支出的关注，北美心臟衰竭 POC 和 LOC 设备产业将在 2024 年至 2032 年间实现可观的复合年增长率。北部拥有完善的医疗基础设施，人们对心臟病的认识不断提高，并强调透过早期准确的诊断来改善患者的治疗结果。对精准医疗的日益重视，加上强有力的医疗保健政策和资金，增加了对先进心臟衰竭监测和诊断设备的需求，推动了区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 心臟衰竭和心血管疾病的盛行率不断增加
  - 诊断技术的进步
  - 政府措施和医疗保健政策
- 产业陷阱与挑战
  - 严格的监管环境
  - 与这些设备相关的高成本
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

主要趋势
蛋白质体测试
代谢组学测试
基因组检测

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

主要趋势
微流控
基于阵列的系统
其他技术

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
专科诊所
辅助生活医疗设施
家庭护理设置
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abaxis, Inc.
Abbott Laboratories
Becton, Dickinson and Company
bioMerieux S.A.
BioTelemetry, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Instrumentation Laboratory
Jant Pharmacal Corporation
Masimo Corporation
Novartis AG
Quidel Corporation
Siemens Healthineers AG
Stryker Corporation
Trinity Biotech

简介目录

Product Code: 9564

Global Heart Failure POC and LOC Devices Market will showcase over 16.4% CAGR from 2024 to 2032, driven by improved healthcare infrastructure. According to the World Health Organization, global healthcare spending reached USD 8.3 trillion in 2022, reflecting a growing investment in advanced medical technologies.

As healthcare systems modernize, there is a greater emphasis on integrating advanced diagnostic technologies into routine practice. This development enhances accessibility and efficiency in detecting and managing heart failure. In both developed and emerging nations, investments in healthcare facilities and technology adoption facilitate broader availability of heart failure Point-of-Care POC and Laboratory-on-a-Chip LOC devices, enabling quicker and more accurate diagnoses. Such advancements improve patient outcomes by meeting the increasing demand for innovative diagnostic solutions, favoring the market outlook.

The heart failure POC and LOC devices industry is categorized based on technology, test type, end-use, and region.

The array-based systems segment will experience a significant CAGR during the forecast period, owing to their ability to provide high-throughput analysis in a single test. Array-based systems offer a multiplexed approach, enabling simultaneous measurement of multiple biomarkers associated with heart failure. This capability enhances diagnostic accuracy and efficiency, facilitating earlier detection and more effective management of the condition. As healthcare providers seek to optimize patient outcomes through more detailed and rapid diagnostics, the adoption of array-based systems in POC and LOC devices for heart failure is expected to increase.

The metabolomic testing segment will hold a noteworthy market share by 2032, because of the growing need for personalized medicine. This test provides detailed insights into metabolic profiles, which improve the precision of heart failure diagnosis and management. As healthcare increasingly shifts toward personalized approaches, the ability to perform rapid, detailed analyses at the point of care or through laboratory-on-a-chip technologies supports more tailored treatment plans. This shift towards precision medicine thrusts the demand for advanced diagnostic devices that quickly deliver comprehensive metabolic data, improving patient outcomes.

North America heart failure POC and LOC devices industry will witness a promising CAGR between 2024 and 2032, due to the focus on innovative healthcare solutions and high medical spending. North With a well-established healthcare infrastructure, there is a heightened awareness of heart disease and an emphasis on improving patient outcomes through early and accurate diagnosis. This growing emphasis on precision medicine, coupled with robust healthcare policies and funding, elevates the demand for advanced heart failure monitoring and diagnostic devices, fueling the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of heart failure and cardiovascular diseases
  - 3.2.1.2 Advancements in diagnostic technologies
  - 3.2.1.3 Government initiatives and healthcare policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory landscape
  - 3.2.2.2 High cost associated with these devices
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Proteomic testing
5.3 Metabolomic testing
5.4 Genomic testing

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Microfluidics
6.3 Array-based systems
6.4 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Assisted living healthcare facilities
7.5 Homecare settings
7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa